DUBLIN--(BUSINESS WIRE)--The "The Corporate Reputation of Pharma, 2017 - The Patient Perspective - US Edition" report has been added to ResearchAndMarkets.com's offering.
US patient groups are traditionally more sceptical and suspicious of pharma than their peers in most of the rest of the world - which makes the 2017 US Corporate Reputation results all the more surprising.
At first glance, not much seems to have changed in 2017. Only 32% of 2017's 169 respondent US-based patient groups thought that the pharma industry as a whole had an "Excellent" or "Good" corporate reputation (compared with 43% of the 1,330 respondent patient groups worldwide). Moreover, US patient groups in 2017 ranked pharma just 5th out of nine healthcare-industry sectors (compared with its ranking of 3rd out of nine among patient groups worldwide).
But a closer analysis of the pharma industry's performance at specific activities reveals a startling turnaround in attitudes in 2017 among some US patient groups [as the charts below show].
A larger proportion of US patient groups than patient groups worldwide in 2017 described the pharma industry as a whole as "Excellent" or "Good" at patient centricity, at integrity, at patient-group partnerships, at the provision of services 'beyond the pill', and at engaging patients/patient groups in R&D.
In fact, the only activity at which US patient groups in 2017 considered pharma to be worse than the global average was innovation (and then only by a small margin - 43% in the US v. 48% worldwide).
Key Topics Covered:
- Executive Summary
- Patient-Group Relationships With Pharma, 2017
- Industry-Wide Findings, 2017
- Rankings Of The 30 Pharma Companies, 2017 V. 2016 Among US Patient Groups Familiar With The Companies
- Positionings Of 28 Pharma Companies, 2017 V. 2016 Among US Patient Groups That Work/Partner With The Companies
- Profiles Of The 30 Companies, 2017
Appendices
I. US Patient Groups: Views On Pharma; And Recommendations For Improvement
Ii. Profiles Of Respondent US Patient Groups, 2017
Companies Mentioned
- Abbvie
- Acorda Therapeutics
- Allergan
- Amgen
- Astellas Pharma
- Astrazeneca
- Bayer
- Biogen
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- Eisai
- Eli Lilly
- Gilead Sciences
- GSK
- Janssen
- Lundbeck
- Merck & Co
- Merck Kgaa
- Novartis
- Novo Nordisk
- Otsuka
- Pfizer
- Roche
- Sanofi
- Shire
- Takeda
- Teva
- UCB
- Vertex Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/research/dk8qpq/corporate?w=4
